Clinical Trial Update: Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications [Phase 3]

View source ↗

Summary

A Phase 3 long-term trial evaluating nateglinide plus valsartan for prevention or delay of type 2 diabetes mellitus and cardiovascular complications has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Complications of Diabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• Nateglinide (nateglinide)
• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2011-05-24